REG - Eden Research plc - Result of General Meeting and Total Voting Rights

Eden ResearchAnnouncement

18/02/2026 09:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260218:nRSR5053Ta&default-theme=true

RNS Number : 5053T  Eden Research plc  18 February 2026

18 February 2026

 

Eden Research plc

("Eden Research" or the "Company")

Result of General Meeting, Director Shareholdings and Total Voting Rights

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and
biocontrol technologies, announces that all resolutions put to Shareholders at
the General Meeting held earlier today in connection with the Placing,
Subscription and Retail Offer, as announced by the Company on 2 February 2026,
were duly passed.

The total number of votes received by proxy on each resolution, as more fully
disclosed in the Notice of General Meeting available on the Company's website,
was as follows:

 

    Resolution                                                                 For                      Against                 Withheld
                                                                               Number of votes  %       Number of votes  %      Number of votes  %
 1  To authorise the Directors to allot relevant securities for cash up to an  181,446,156      99.51%  901,567          0.49%  2,033,070        -
    aggregate nominal amount of £2,787,500, being equal to 278,750,000 New

    Ordinary Shares
 2  To authorise the Directors to allot 278,750,000 New Ordinary Shares on a   181,338,467      99.45%  1,001,567        0.55%  2,040,759        -
    non-pre-emptive basis

 

·      A vote Withheld is not a vote in law and is not counted in the
calculation of the votes cast For or Against the resolution, nor in the
calculation of the percentage of issued share capital voted for any
resolution.

·      Votes For and Against are expressed as a percentage of votes
validly cast for that resolution by proxy, excluding any Withheld votes.

 

 Director Shareholdings

The following Directors subscribed for New Ordinary Shares pursuant to the
Fundraising. The number of new Ordinary Shares subscribed for by each Director
and their resulting shareholdings upon Admission are set out below:

 Name                  Number of existing Ordinary Shares  Number of Firm  Shares subscribed for ((1))    Number of Ordinary Shares held following Admission
 Lykele van der Broek  2,357,808                           1,125,000                                      3,482,808
 Sean Smith            3,059,768                           500,000                                        3,559,768
 Alex Abrey            3,181,678                           500,000                                        3,681,678
 Derek McAllan         843,627                             250,000                                        1,093,627

 

(1)  The number of Ordinary Shares presented in this table as being held or
subscribed for by Directors refers to the number of Ordinary Shares held or
subscribed for by them either personally or through a nominee.

 

The notifications below, made in accordance with the requirements of the UK
Market Abuse Regulation, provide further details.

 

Admission and Total Voting Rights

Following shareholder approval at the general meeting and conditional on First
Admission, a total of 80,010,471 New Ordinary Shares (comprising 74,875,000
Firm Placing Shares, 1,375,000 Firm Subscription Shares and 3,760,471 Retail
Offer Shares will be admitted to trading on AIM ("Admission") at 8.00 a.m. on
or around 19 February 2026.

Following First Admission, the total number of Ordinary Shares in the capital
of the Company in issue will be 613,362,994 with each Ordinary Share carrying
the right to one vote. There are no shares held in treasury and therefore,
following Admission, the total number of voting rights in the Company will be
613,362,994.

The above figure may be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure, Guidance and Transparency Rules.

Capitalised terms used in this announcement have the meaning given to them in
the announcement dated 2 February 2026 and 6 February 2026, unless otherwise
defined in this announcement.

 

Enquiries:

 Eden Research plc                                                       www.edenresearch.com (http://www.edenresearch.com/)
 Sean Smith                                                              01285 359 555

Alex Abrey

 Cavendish Capital Markets Limited (Nominated advisor and joint broker)
 Giles Balleny / Elysia Bough (Corporate Finance)                        020 7220 0500

 Harriet Ward (Corporate Broking)

Dale Bellis (Sales)

 Oberon Capital (Joint Broker)                                           020 3179 5300
 Nick Lovering

 Mike Seabrook

 Adam Pollock

 Hawthorn Advisors (Financial PR)
 Victoria Ainsworth                                                      eden@hawthornadvisors.com

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

  1   Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         1.  Lykele van der Broek

                                                                   2.  Sean Smith

                                                                   3. Alex Abrey

                                                                   4. Derek McAllan
 2    Reason for the notification
 a)   Position/status                                              1.   Chairman

                                                                   2.   Chief Executive Officer

                                                                   3.   Chief Financial Officer

                                                                   4.   Non-Executive Director

 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         Eden Research plc
 b)   LEI                                                          213800ZWTYTVQQSM3J85
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1 pence each

      Identification code

                                                                    GB0001646941

 b)   Nature of the transaction                                    1 & 4: Subscription for New Ordinary Shares

                                                                   2 & 3: Subscription for New Ordinary Shares through Placing
 c)   Price(s) and volume(s)

  Price    Volume
                                                                   1 4 pence  1,125,000
                                                                   2 4 pence  500,000
                                                                   3 4 pence  500,000
                                                                   4 4 pence  250,000
 d)   Aggregated information                                        N/A - single transaction

       - Aggregated volume

       - Price
 e)   Date of the transaction                                      18 February 2026

 f)   Place of the transaction                                     Outside a trading venue

d)

 

Aggregated information

 - Aggregated volume

 - Price

 N/A - single transaction

e)

Date of the transaction

18 February 2026

 

f)

Place of the transaction

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMGCGDDIXBDGLI



            Copyright 2019 Regulatory News Service, all rights reserved